Nelfinavir+M8 plasma levels determined with an ELISA test in HIV infected patients with or without HCV and/or HBV coinfection: the VIRAKINETICS II study.

Curr HIV Res 2009 May;7(3):293-301

Infectious Disease Dept., Foundation IRCCS Policlinico San Matteo Hospital - Pavia, Italy.

Virakinetics II was designed as an observational, multicenter cohort study conducted in HIV-positive patients treated with NFV-based combinations. Trough (pre-dose) concentrations of NFV+M8 in plasma were determined using a novel ELISA test (NFV TDM-ELISA) and analyzed using clinical and laboratory parameters. Drug levels were sorted as below, within or above a given interval (<0.8 microg/mL, 0.8-3.5 microg/mL and >3.5 microg/mL, respectively). Longitudinal analysis was performed in a subset of patients who underwent two or more determinations. Ninety patients on NFV-containing HAART were enrolled and 43 were coinfected with HCV and/or HBV. Among coinfected patients, 10 subjects had a clinical or histological diagnosis of cirrhosis. Compared to the HIV-monoinfected, the coinfected patients were significantly older, more treatment-experienced, with higher frequency of lipodystrophy and altered liver function test values (all p values: <0.05). Coinfected patients were also more likely to be on a reduced dose of NFV than monoinfected (p=0.03). No significant difference was observed between the two groups with regard to NFV+M8 trough values and concentration range distribution. Median NFV+M8 C(trough) concentrations were higher in coinfected patients, but without reaching statistical significance (p=0.2). This new ELISA test proved to be a rapid, convenient and reliable tool for assessing NFV+M8 plasma levels in HIV-positive patients. It could be suitable for use within the framework of routine clinical practice even in peripheral centers without specialized laboratories.

Download full-text PDF

Source
http://dx.doi.org/10.2174/157016209788347967DOI Listing
May 2009
21 Reads

Publication Analysis

Top Keywords

elisa test
8
hcv and/or
8
coinfected patients
8
and/or hbv
8
patients
6
tdm-elisa analyzed
4
hiv-monoinfected coinfected
4
nfv tdm-elisa
4
parameters drug
4
cirrhosis compared
4
laboratory parameters
4
compared hiv-monoinfected
4
test nfv
4
analyzed clinical
4
clinical laboratory
4
patients older
4
pre-dose concentrations
4
treatment-experienced higher
4
coinfected hcv
4
combinations trough
4

Similar Publications